Associated Papers
Clinical Implementation of Pharmacogenomics and Drug-Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow-Up.
Tremmel R et al.
Clinical Pharmacology and Therapeutics, 2026
41074844 (PubMed )
Supplement: CPT-119-241-s005.pdf
Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy.
Hoste E et al.
Clinical Biochemistry, 2024
Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics.
Brunet M et al.
Pharmaceutics, 2022
Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components.
Turner RM et al.
Journal of Clinical Medicine, 2019
31861911 (PubMed )
Supplement: jcm-09-00022-s001.pdf
Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation.
Yu M et al.
Current Drug Metabolism, 2018
The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Transplant Recipients.
Madsen MJ et al.
Drugs in R&d, 2017
Modelling of atorvastatin pharmacokinetics and the identification of the effect of a BCRP polymorphism in the Japanese population.
Tsamandouras N et al.
Pharmacogenetics and Genomics, 2017
Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
Tang JT et al.
Expert Opinion on Drug Metabolism & Toxicology, 2016
The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
Lunde I et al.
European Journal of Clinical Pharmacology, 2014
Select a paper to view details